Du är här

2016-02-25

MorphoSys AG: Invitation to Year End 2015 Conference Call of MorphoSys AG on March 2, 2016

MorphoSys AG / Invitation to Year End 2015 Conference Call of MorphoSys AG on
March 2, 2016. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its
Annual Financial Results 2015 on March 2, 2016 at 7:00 a.m. CET.

The Management team of MorphoSys AG will host a conference call and webcast to
present MorphoSys's Annual Financial Results 2015 and provide an outlook for
2016.

Date: Wednesday, March 2, 2016
Time: 02:00 p.m. CET (01:00 p.m. GMT, 08:00 a.m. EST)

Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA: +1 202 204 1514

Participants of the call will be:
Dr. Simon Moroney, Chief Executive Officer
Jens Holstein, Chief Financial Officer
Dr. Arndt Schottelius, Chief Development Officer
Dr. Marlies Sproll, Chief Scientific Officer

We request that you please dial in up to 10 minutes before the call to ensure
a prompt start and a secure line.

The presentation slides and webcast link will be available at the Company's
website atwww.morphosys.com/conference-calls

A slide-synchronized audio replay of the conference will also be available at
the corporate website following the live event.

About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few.
With its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys
is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular
updates about MorphoSys, visithttp://www.morphosys.com.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®,
100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are
registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and
involve risks and uncertainties, Should actual conditions differ from the
Company's assumptions, actual results and actions may differ from those
anticipated, MorphoSys does not intend to update any of these forward-looking
statements as far as the wording of the relevant press release is concerned

For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications&IR

Alexandra Goller
Senior Manager Corporate Communications&IR

Jochen Orlowski
Associate Director Corporate Communications&IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

YE 2015 Conference Call Alert
http://hugin.info/130295/R/1988883/730410.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: MorphoSys AG via Globenewswire

HUG#1988883

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.